資訊|論壇|病例

搜索

首頁(yè) 醫(yī)學(xué)論壇 專業(yè)文章 醫(yī)學(xué)進(jìn)展 簽約作者 病例中心 快問(wèn)診所 愛(ài)醫(yī)培訓(xùn) 醫(yī)學(xué)考試 在線題庫(kù) 醫(yī)學(xué)會(huì)議

您所在的位置:首頁(yè) > 腫瘤科診療指南 > 2009CCO肛管鱗狀細(xì)胞癌診治指南

2009CCO肛管鱗狀細(xì)胞癌診治指南

2014-05-04 16:20 閱讀:1716 來(lái)源:愛(ài)愛(ài)醫(yī) 作者:若****人 責(zé)任編輯:若你喜歡怪人
[導(dǎo)讀] The management of patients wholater develop extra-pelvic metastases is not considered in this guideline.

    《2009CCO肛管鱗狀細(xì)胞癌診治指南》內(nèi)容簡(jiǎn)介:

    These recommendations apply to ** patients (age ≥18 years) with a primarydiagnosis of biopsy-proven squamous cell cancer of the ** c**, including basaloid,cloacogenic, and transitional cell tumours. These recommendations do not apply to patientswho have previously undergone resection of their tumour.The management of patients wholater develop extra-pelvic metastases is not considered in this guideline.

    《2009CCO肛管鱗狀細(xì)胞癌診治指南》內(nèi)容預(yù)覽:

 
   RECOMMENDATIONS

    For all stages of localized squamous cell cancer of the ** c**, concurrent CT and RT isrecommended over RT alone to improve local control and decrease colostomy rates.

    The optimal CT drug combination for squamous cell cancer of the ** c** is 5-fluorouracil (5FU) plus mitomycin C (MMC), given concurrently with radiation treatment.

    At this time, induction CT before concurrent CT and RT should be considered aninvestigational approach.

    It is the expert opinion of the Gastrointestinal Cancer Disease Site Group (GI DSG) thatHIV-positive patients with squamous cell cancer of the ** c** should be managed inthe same way as patients without known HIV. Treating physicians should be aware that agreater than average risk of toxicity is possible.

    點(diǎn)擊下載***:《2009CCO肛管鱗狀細(xì)胞癌診治指南》


分享到:
  版權(quán)聲明:

  本站所注明來(lái)源為"愛(ài)愛(ài)醫(yī)"的文章,版權(quán)歸作者與本站共同所有,非經(jīng)授權(quán)不得轉(zhuǎn)載。

  本站所有轉(zhuǎn)載文章系出于傳遞更多信息之目的,且明確注明來(lái)源和作者,不希望被轉(zhuǎn)載的媒體或個(gè)人可與我們

  聯(lián)系z(mì)lzs@120.net,我們將立即進(jìn)行刪除處理

意見(jiàn)反饋 關(guān)于我們 隱私保護(hù) 版權(quán)聲明 友情鏈接 聯(lián)系我們

Copyright 2002-2024 Iiyi.Com All Rights Reserved